research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
Search
for
Sort by
Research
300-330 / 1000+ results 
research Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
research Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IGG AND IGA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE
Higher antigliadin antibody levels are linked to alopecia areata severity.
research Correlation between serum brain-derived neurotrophic factor level and depression severity in alopecia areata patients
Lower BDNF levels link to worse depression in alopecia areata patients.
research ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IgG and IgA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE
Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
research Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.
research Assessment of Alopecia Areata Disease Severity in Pediatric Patients
New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
research Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
research The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.
research Factors Affecting the Psychosocial Distress of Patients with Alopecia Areata: A Nationwide Study in Korea
Many patients with Alopecia Areata in Korea experience anxiety, depression, and reduced quality of life, which are often unrelated to the severity of hair loss.
research Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross‐sectional cohort study
Alopecia areata greatly affects the quality of life for children and their families.
research Severity Prediction of Hair Loss in Alopecia Areata with Hybrid Deep Learning Architecture
The model accurately predicts hair loss severity in alopecia areata.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
Baricitinib is effective and safe for treating severe alopecia areata.
research Comparison of Trichoscopic Features of Alopecia Areata before and after Treatment with Intralesional Steroids
Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.
research Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
research Extensive alopecia areata: Not necessarily recalcitrant to therapy!
Some people with severe, long-lasting baldness responded well to a specific combination treatment.
research Assessment of miR-19b-3p, miR-182-5p, and miR-155-5p expression and its relationship with alopecia areata severity
miR-155-5p can help diagnose and track alopecia areata severity.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Quality of Life in Alopecia Areata: A Study of 60 Cases
Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.
research Dermoscopic findings of alopecia areata in dark skinned individuals: An analysis of 116 cases
The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.
research Comparative Efficacy and Adverse Clinical Events of Methotrexate versus Azathioprine with Steroid Mini Pulse Therapy in the Management of Moderate to Severe Alopecia Areata: A Tertiary Centre Based Interventional Study
Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel
Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.